Bristol-Myers Squibb rises on report of AstraZeneca merger talks
+0.24% to $65.47 from $65.31
What moved BMY
- The Financial Times reported over the weekend that Bristol-Myers Squibb held preliminary talks with AstraZeneca about a potential merger that would combine two of the industry’s largest drugmakers.
- Reuters, citing a person familiar with the matter, confirmed the discussions were at a preliminary stage.
- The news added to gains from the prior week, when Bristol-Myers Squibb topped second-quarter estimates and raised its full-year sales and earnings guidance.
Sources: Financial Times · Reuters · Investing.com